JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB248942

Anti-CYP2C9 antibody [EPR7340] - BSA and Azide free

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal CYP2C9 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication.

View Alternative Names

CYP2C10, CYP2C9, Cytochrome P450 2C9, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC9, Cholesterol 25-hydroxylase, Cytochrome P-450MP, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, S-mephenytoin 4-hydroxylase

1 Images
Western blot - Anti-CYP2C9 antibody [EPR7340] - BSA and Azide free (AB248942)
  • WB

Lab

Western blot - Anti-CYP2C9 antibody [EPR7340] - BSA and Azide free (AB248942)

This data was developed using ab150364, the same antibody clone in a different buffer formulation.

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

ab181602 was used a loading control for GAPDH.

Exposure time :

Lanes 1,2 : 3 seconds

Lanes 3,4 : 10 seconds

WB result showed an additional band at 37kDa in HepG2 cell lysate, we are unsure as to identify of it.

All lanes:

Western blot - Anti-CYP2C9 antibody [EPR7340] (<a href='/en-us/products/primary-antibodies/cyp2c9-antibody-epr7340-ab150364'>ab150364</a>) at 1/10000 dilution

Lane 1:

293T (Human embryonic kidney epithelial cell) transfected with His-tagged empty vector, whole cell lysate at 20 µg

Lane 2:

293T (Human embryonic kidney epithelial cell) transfected with His-tagged CYP2C9 expression vector, whole cell lysate at 20 µg

Lane 3:

Human liver lysate at 20 µg

Lane 4:

HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Observed band size: 56 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR7340

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Complementary Products

Primary Antibodies

AB124921

Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921)

  • 4
  • 1
Primary Antibodies

AB137015

Anti-CYP2C19 antibody [EPR6576]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2C19 antibody [EPR6576] (AB137015)

  • 0
  • 0
Primary Antibodies

AB185625

Anti-CYP2D6 antibody [EPR17868]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2D6 antibody [EPR17868] (AB185625)

  • 0
  • 0
Primary Antibodies

AB151728

Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome P450 1A2 antibody [EPR6138(2)] (AB151728)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>" } } }
style
left-column

Product details

ab248942 is the carrier-free version of ab150364.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 2C9 often abbreviated as CYP2C9 is an enzyme belonging to the cytochrome P450 family known for its function in drug metabolism. CYP2C9 possesses an approximate mass of 55kDa and is found predominantly in the liver where it is highly expressed. As a heme-thiolate monooxygenase its mechanical action involves the oxidation of structurally diverse endogenous and exogenous compounds. These compounds include drugs steroids and fatty acids converting them into more water-soluble metabolites. Its role as a cytochrome P450 enzyme makes it an important target for CYP2C9 inhibitor assays used in various studies.
Biological function summary

CYP2C9 plays a significant role in drug metabolism and detoxification within the body including warfarin phenytoin and tolbutamide. It is a part of the extensive cytochrome P450 complex that is vital for the monooxygenation of various substrates. The enzyme acts on many drugs involved in anticoagulation anti-inflammatory processes and oral hypoglycemics facilitating their clearance from the body and influencing their pharmacokinetics and pharmacodynamics. Researchers conduct in vitro systems to test CYP2C9 activity and its inhibition contributing to drug safety evaluations.

Pathways

CYP2C9 integrates into the drug metabolism and lipid biosynthesis pathways. It works closely with other cytochrome P450 enzymes like CYP3A4 and CYP2C19 in metabolizing xenobiotics and endogenous substrates. In the arachidonic acid pathway CYP2C9 converts arachidonic acid to epoxyeicosatrienoic acids (EETs) which play roles in blood pressure regulation and inflammatory responses. These pathways highlight the importance of matching CYP2C9 and its related proteins to specific clinical outcomes particularly in the metabolism of various pharmaceutical agents.

CYP2C9 exhibits significant associations with bleeding disorders related to warfarin metabolism and with phenytoin-induced toxicity. Genetic polymorphisms of CYP2C9 can result in altered enzyme activity leading to variable drug responses and adverse drug reactions particularly in medications with a narrow therapeutic index. The enzyme strongly interacts with VKORC1 in the context of warfarin therapy and mutations can cause issues in dose management. Understanding these interactions helps refine therapeutic strategies adjusting drug dosing to reduce risks of toxicity or therapeutic failure.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed : 12865317, PubMed : 15766564, PubMed : 19965576, PubMed : 21576599, PubMed : 7574697, PubMed : 9435160, PubMed : 9866708). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed : 12865317, PubMed : 15766564, PubMed : 19965576, PubMed : 21576599, PubMed : 7574697, PubMed : 9435160, PubMed : 9866708). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed : 15766564, PubMed : 19965576, PubMed : 7574697, PubMed : 9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed : 21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed : 12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed : 9435160, PubMed : 9866708). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed : 11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed : 25994031).
See full target information CYP2C9
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of personalized medicine 12: PubMed35207643

2022

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Spyridoula D Katsarou,Ippokratis Messaritakis,Anastasia Voumvouraki,Stavros Kakavogiannis,Athanasios Κotsakis,Saad Alkahtani,Christos Stournaras,Stuart S Martin,Vassilis Georgoulias,Galatea Kallergi
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com